Sandbox sss: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
No edit summary
Line 12: Line 12:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]''''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]<BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV''''' 
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]<BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 39: Line 39:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]<BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Cefotaxime or Ceftriaxone MIC† >1.0 μg/mL}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Cefotaxime or Ceftriaxone MIC† >1.0 μg/mL}}
Line 57: Line 57:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]''''' <BR>''OR''<BR> ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h''''' <BR>''OR''<BR> ▸ '''''[[Ceftriaxone]]<BR>        1 gm IV qd <BR>''OR''<BR>      2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Moxifloxacin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Moxifloxacin]] 400 mg po IV q24h '''''
|-
|-
|}
|}
Line 86: Line 86:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]<BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''  
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-


| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]<BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]]'''''<BR><BR><BR>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''<BR><BR><BR>
|-
|-
|}
|}
Line 114: Line 114:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] <BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 134: Line 134:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
|-
|-
|}
|}
Line 142: Line 142:


{|
{|
|-
|-
| valign=top |
| valign=top |
Line 151: Line 150:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''  
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-


| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]<BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-


| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5–20 mg/kg/day q6-12h '''''
|-
|-
|}
|}
Line 170: Line 169:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-


| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] <BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-


| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] <BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''

Revision as of 17:24, 16 January 2014

Meningitis Main Page

Patient Information

Overview

Causes

Classification

Viral Meningitis
Bacterial Meningitis
Fungal Meningitis

Differential Diagnosis

Diagnosis

Treatment


Streptococcus pneumoniae

Penicillin MIC ≤0.06 μg/mL
Preferred Regimen
Penicillin G
Low: 600,000–1.2 million units/day IM
High:≥ 20 million units IV q24h(=12 gm)
OR
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
Alternative Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone
1 gm IV qd
OR
2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Chloramphenicol
Penicillin MIC ≥0.12 μg/mL
Cefotaxime or Ceftriaxone MIC† <1.0 μg/mL
Preferred Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone
1 gm IV qd
OR
2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 gm IV q12h
OR
Meropenem 2 gm IV q8h
Cefotaxime or Ceftriaxone MIC† >1.0 μg/mL
Preferred Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
AND
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone
1 gm IV qd
OR
2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
AND
Moxifloxacin 400 mg po IV q24h

Neisseria meningitidis

Neisseria meningitidis
Penicillin MIC <0.1 μg/mL
Preferred Regimen
Penicillin G
Low: 600,000–1.2 million units/day IM
High:≥ 20 million units IV q24h(=12 gm)
OR
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
Alternative Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone
1 gm IV qd
OR
2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Chloramphenicol 0.25–1 gm po IV q6h to max. of 4 gm/day


Neisseria meningitidis
Penicillin MIC ≥0.1 μg/mL
Preferred Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone
1 gm IV qd
OR
2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 gm IV q12h
OR
Chloramphenicol 0.25–1 gm po IV q6h to max. of 4 gm/day
OR
Fluoroquinolone
OR
Meropenem 2 gm IV q8h

Listeria Monocytogenes and Streptococcus agalactiae

Listeria Monocytogenes
Preferred Regimen
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
OR
Penicillin G
Low: 600,000–1.2 million units/day IM
High:≥ 20 million units IV q24h(=12 gm)
Alternative Regimen
Trimethoprim-sulfamethoxazole 5–20 mg/kg/day q6-12h
Streptococcus agalactiae
Preferred Regimen
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
OR
Penicillin G
Low: 600,000–1.2 million units/day IM
High:≥ 20 million units IV q24h(=12 gm)
Alternative Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone
1 gm IV qd
OR
2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Vancomycin


Haemophilus influenzae

Haemophilus influenzae
β-lactamase negative
Preferred Regimen (Adult)
Ampicillin
Preferred Regimen (Pediatric)
Ampicillin
Alternative Regimen (Adult)
Cefotaxime
OR
Ceftriaxone
OR
Cefepime
OR
Chloramphenicol
OR
Aztreonam
OR
Fluoroquinolone
Alternative Regimen (Pediatric)
Cefotaxime
OR
Ceftriaxone
OR
Cefepime
OR
Chloramphenicol
OR
Aztreonam
OR
Fluoroquinolone
Haemophilus influenzae
β-lactamase positive
Preferred Regimen
Cefotaxime
OR
Ceftriaxone
Alternative Regimen
Cefepime
OR
Chloramphenicol,
OR
Aztreonam
OR
Fluoroquinolone
Haemophilus influenzae
β-lactamase negative, ampicillin resistant
Preferred Regimen
Meropenem
Alternative Regimen
Fluoroquinolone

Staphylococcus aureus

Staphylococcus aureus
Meticillin sensitive
Preferred Regimen
Nafcillin
OR
Oxacillin
Alternative Regimen
Vancomycin
OR
linezolid
OR
Daptomycin
Staphylococcus aureus
Meticillin resistant
Preferred Regimen
Vancomycin
Alternative Regimen
Trimethoprim-sulfamethoxazole
OR
linezolid
OR
Daptomycin


Staphylococcus epidermidis and Acinetobacter baumannii

Staphylococcus epidermidis
Preferred Regimen
Vancomycin
Alternative Regimen
Linezolid


Acinetobacter baumannii
Preferred Regimen
Meropenem
Alternative Regimen
Colistin
OR
Polymyxin B

Enterobacteriaceae and Pseudomonas aeruginosa

Enterobacteriaceae
Preferred Regimen
Cefotaxime
OR
Ceftriaxone
Alternative Regimen
Aztreonam
OR
Fluoroquinolone
OR
Trimethoprim-sulfamethoxazole
OR
Meropenem
OR
Ampicillin
Pseudomonas aeruginosa
Preferred Regimen
Ceftazidime
OR
Cefepime
Alternative Regimen
Aztreonam
OR
Meropenem
OR
Ciprofloxacin